GOLD sponsor
|
|
|
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring lifechanging medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. |
|
|
| Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics. The Menarini Group is present in 140 countries around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market. Thanks to the valuable contribution of over 17,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients. Our drugs are distributed across 6 continents for the treatment of pathologies in cardiology, oncology, pneumology, inflammation and gastroenterology. Menarini invests in the future and guarantees drug availability in the present for the improvement of patient health and well-being. In its 9 Research and Development centers, Menarini’s main focus is dedicated to therapeutic areas with unresolved pathologies, such as oncology and anti-infectives (AMR), where increasing treatment options is fundamental to helping those in need. The Group's pipeline concentrates on innovative drugs and technologies including both small molecule and biologics for hematologic and solid tumors for greater personalized solutions. |
|
|
| Novartis is re-imagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. |
Exhibitors
|
|
|
3rd Annual International Oncology Forum
© Copyright 2024 | 3rd Annual International Oncology Forum